KARAMOUZA, Eleni; GLASSPOOL, Rosalind M.; KELLY, Caroline; LEWSLEY, Liz-Anne; CARTY, Karen; KRISTENSEN, Gunnar B.; ETHIER, Josee-Lyne; KAGIMURA, Tatsuo; YANAIHARA, Nozomu; CECERE, Sabrina Chiara; YOU, Benoit; BOERE, Ingrid A; PUJADE-LAURAINE, Eric; RAY-COQUARD, Isabelle; PROUST LIMA, Cecile; PAOLETTI, Xavier

doi:10.3390/cancers15061823

Langue

Article de revue

Ce document a été publié dans

Cancers. 2023-03-17, vol. 15, n° 6

Résumé en anglais

(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients' monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy.< Réduire

Mots clés en anglais

Ovarian cancer

CA-125

Biomarker

Linear mixed model

Meta-analysis

URI

https://oskar-bordeaux.fr/handle/20.500.12278/173043

DOI

http://dx.doi.org/10.3390/cancers15061823

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche